Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here